Selected publications

Vivas I, Iribarren K, Lozano T, Cano D, Lasarte-Cia A, Chocarro S, Gorraiz M, et al. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. J Vasc Interv Radiol 2019.

Lasarte-Cia A, Lozano T, Pérez-González M, Gorraiz M, Iribarren K, Hervás-Stubbs S, Sarobe P, et al. Immunomodulatory properties of Carvone inhalation and its effects on contextual fear memory in mice. Frontiers in Immunology 2018;In press.

Celay J, Lozano T, Concepcion AR, Beltran E, Rudilla F, Garcia-Barchino MJ, Robles EF, et al. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. Haematologica 2018;103:1065-1072.

San Jose-Eneriz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun 2017;8:15424.

Moreno Ayala MA, Gottardo MF, Imsen M, Asad AS, Bal de Kier Joffe E, Casares N, Lasarte JJ, et al. Therapeutic blockade of Foxp3 in experimental breast cancer models. Breast Cancer Res Treat 2017;166:393-405.

Lozano T, Gorraiz M, Lasarte-Cia A, Ruiz M, Rabal O, Oyarzabal J, Hervas-Stubbs S, et al. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. Oncotarget 2017;8:71709-71724.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bertolo C, et al. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discov 2017;7:694-703.

Rollier CS, Verschoor EJ, Verstrepen BE, Drexhage JA, Paranhos-Baccala G, Liljestrom P, Sutter G, et al. T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. Gene Ther 2016;23:753-759.

Lozano T, Soldevilla MM, Casares N, Villanueva H, Bendandi M, Lasarte JJ, Pastor F. Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials 2016;91:73-80.

San Miguel JF, Paiva B, Lasarte JJ. Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. Cancer Cell 2015;28:281-283.

Melero I, Lasarte JJ. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 2015;372:783.

Matsoukas MT, Aranguren-Ibanez A, Lozano T, Nunes V, Lasarte JJ, Pardo L, Perez-Riba M. Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners. Sci Signal 2015;8:ra63.

Lozano T, Villanueva L, Durantez M, Gorraiz M, Ruiz M, Belsue V, Riezu-Boj JI, et al. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. J Immunol 2015;195:3180-3189.

Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-88.

Lozano T, Casares N, Lasarte JJ. Searching for the Achilles Heel of FOXP3. Front Oncol 2013;3:294.

Arribillaga L, Durantez M, Lozano T, Rudilla F, Rehberger F, Casares N, Villanueva L, et al. A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo. Biomed Res Int 2013;2013:864720.

Rudilla F, Fayolle C, Casares N, Durantez M, Arribillaga L, Lozano T, Villanueva L, et al. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine 2012;30:2848-2858.

Mansilla C, Berraondo P, Durantez M, Martinez M, Casares N, Arribillaga L, Rudilla F, et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int J Cancer 2012;131:641-651.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011;208:491-503.

Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borras-Cuesta F, Lasarte JJ, Sarobe P, et al. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 2011;53:327-333.

Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, Lopez-Sagaseta J, et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 2010;185:5150-5159.

Gil-Guerrero L, Dotor J, Huibregtse IL, Casares N, Lopez-Vazquez AB, Rudilla F, Riezu-Boj JI, et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 2008;181:126-135.

Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, Durantez M, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007;178:748-756.

Lasarte JJ, Sarobe P, Boya P, Casares N, Arribillaga L, de Cerio AL, Gorraiz M, et al. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. Hepatology 2003;37:461-470.

Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171:5931-5939.

"We have identified specific proteins and peptides capable of transporting antigens to the dendritic cells. With these molecules, we are managing to increase the immunogenicity of the vaccines", Juan José Lasarte.


Cristina López
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700 Ext. 6021